| Name | Title | Contact Details |
|---|
Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
3DBio is the first company implanting personalized 3D-printed living tissues in patients. #3DBioPrinting #3DBio
Syreon Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.